|Table of Contents|

Analysis of the efficacy and prognostic factor of intensity-modulated radiotherapy for nasopharyngeal carcinoma(691 cases)

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2022 05
Page:
801-806
Research Field:
Publishing date:

Info

Title:
Analysis of the efficacy and prognostic factor of intensity-modulated radiotherapy for nasopharyngeal carcinoma(691 cases)
Author(s):
WU Shihai; XU Gang; QUAN Rencui; YANG Dong; LIU Jingwen; CHEN Shanyi; WU Dong; YAN Maosheng; ZHOU Yayan; LI Zihuang; LI Xianming
Department of Radiation Oncology,the First Affiliated Hospital of Southern University of Science and Technology,Second Clinical Medicine College of Jinan University,Shenzhen People's Hospital,Guangdong Shenzhen 518000,China.
Keywords:
nasopharyngeal carcinoma; survival analysis; intensity-modulated radiotherapy(IMRT); concurrent chemotherapy
PACS:
R739.6
DOI:
10.3969/j.issn.1672-4992.2022.05.009
Abstract:
Objective:To retrospectively analyze the survival outcome and prognostic factors for patients with nasopharyngeal carcinoma(NPC) receiving intensity-modulated radiotherapy(IMRT).Methods:Clinical data of 691 patients with NPC receiving IMRT from January 2009 to August 2015 were collected.Survival analysis and prognostic factors were performed and analyzed.Results:The median follow-up time was 62.8 months.The 5-year overall survival rate(OS),disease-special survival rate(DSS),progression-free survival rate(PFS),locoregional recurrence free survival rate(LRFS) and distant metastasis free survival rate(DMFS) were 85.8%,86.5%,82.5%,90.7% and 89.4%,respectively.The 5-year LRFS and DMFS of phase Ⅰ,Ⅱ,Ⅲ and Ⅳa were 100.0% and 100.0%,99.2% and 96.0%,93.5% and 92.7%,83.4% and 76.1%,respectively.A total of 109 patients died(102 died of tumor and 7 died of non-tumor).63 patients experienced relapse,44 cases(70.0%) occurred within 3 years,and only 6 cases(9.5%) occurred over 5 years.72 cases metastasized,63 cases(87.5%) occurred within 3 years,and only 1 case(1.4%) occurred over 5 years.Gender,T stage and N stage were the prognostic factors of OS,DSS,PFS,LRFS and DMFS.Patients with or without induction chemotherapy had 5-year DSS of 95.8% vs 89.3%(P＜0.05) and 92.8% vs 85.5%(P＜0.05) in stage Ⅲ and Ⅳa NPC.While the 5-year DSS of patients with or without concurrent chemotherapy in stage Ⅲ and Ⅳa NPC were 73.1% vs 68.9%(P＜0.05) and 72.7% vs 53.0%(P＜0.05).Conclusion:IMRT improves the survival rate of NPC patients.Recurrence or metastasis mainly occurs within 2 to 3 years after radiotherapy.Induction and concurrent chemotherapy improve the 5-year DSS of patients with locally advanced NPC.

References:

[1]YU MC.Nasopharyngeal carcinoma:epidemiology and dietary factors［J］.IARC Sci Publ,1991(105):39-47.
[2]苏胜发,赵充,韩非,等.鼻咽癌适形调强放疗远期疗效分析［J］.中华肿瘤防治杂志,2013,20(11):853-858. SU SF,ZHAO C,HAN F,et al.Long-term outcome of nasopharyngeal carcinoma patients treated with intensity modulated radiotherapy［J］.Chinese Journal of Cancer Prevention and Treatment,2013,20(11):853-858.
[3]邱慧芝,王琳婧,莫浩元,等.905例鼻咽癌远期疗效及失败模式的探讨［J］.肿瘤学杂志,2018,24(06):555-561. QIU HZ,WANG LJ,MO HY,et al.Long-term outcomes and treat failure mode of 905 nasopharyngeal carcinoma patients treated with radiotherapy［J］.Journal of Chinese Oncology,2018,24(06):555-561.
[4]徐丽贤,黄生富,陈亚楠,等.195例鼻咽癌调强放疗的远期疗效及预后分析［J］.临床肿瘤学杂志,2015,20(9):813-818. XU LX,HUANG SF,CHEN YN,et al.Long-term outcome and prognostic factor analysis in 195 cases of nasopharyngeal carcinoma treated with intensity-modulated radiotherapy［J］.Chinese Clinical Oncology,2015,20(9):813-818.
[5]CHUA M,WEE J,HUI EP,et al.Nasopharyngeal carcinoma［J］.Lancet,2016,387(10022):1012-1024.
[6]LIANG SB,WANG Y,HU XF,et al.Survival and toxicities of IMRT based on the RTOG protocols in patients with nasopharyngeal carcinoma from the endemic regions of China［J］.J Cancer,2017,8(18):3718-3724.
[7]TIAN YM,LIU MZ,ZENG L,et al.Long-term outcome and pattern of failure for patients with nasopharyngeal carcinoma treated with intensity-modulated radiotherapy［J］.Head Neck,2019,41(5):1246-1252.
[8]JIANG F,JIN T,FENG XL,et al.Long-term outcomes and failure patterns of patients with nasopharyngeal carcinoma staged by magnetic resonance imaging in intensity-modulated radiotherapy era:The Zhejiang Cancer Hospital's experience［J］.J Cancer Res Ther,2015,11(Suppl 2):C179-C184.
[9]QIN DX,HU YH,YAN JH,et al.Analysis of 1379 patients with nasopharyngeal carcinoma treated by radiation［J］.Cancer,1988,61(6):1117-1124.
[10]LEE AW,POON YF,FOO W,et al.Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 1976-1985:overall survival and patterns of failure［J］.Int J Radiat Oncol Biol Phys,1992,23(2):261-270.
[11]AU KH,NGAN RK C,NG AWY,et al.Treatment outcomes of nasopharyngeal carcinoma in modern era after intensity modulated radiotherapy(IMRT) in Hong Kong:A report of 3328 patients(HKNPCSG 1301 study)［J］.Oral Oncology,2018,77:16-21.
[12]田允铭,韩非,曾雷,等.鼻咽癌调强放疗后长期生存结果及失败模式分析［J］.中华放射肿瘤学杂志,2018,27(10):880-885. TIAN YM,HAN F,ZENG L,et al.Long-term survival outcome and failure pattern after intensity-modulated radiotherapy for nasopharyngeal carcinoma［J］.Chinese Journal Radiation Oncology,2018,27(10):880-885.
[13]SETTON J,HAN J,KANNARUNIMIT D,et al.Long-term patterns of relapse and survival following definitive intensity-modulated radiotherapy for non-endemic nasopharyngeal carcinoma［J］.Oral Oncol,2016,53:67-73.
[14]SUN X,SU S,CHEN C,et al.Long-term outcomes of intensity-modulated radiotherapy for 868 patients with nasopharyngeal carcinoma:An analysis of survival and treatment toxicities［J］.Radiotherapy and Oncology,2014,110(3):398-403.
[15]XUE F,HU C,HE X.Long-term patterns of regional failure for nasopharyngeal carcinoma following intensity-modulated radiation therapy［J］.J Cancer,2017,8(6):993-999.
[16]MAO YP,LIANG SB,LIU LZ,et al.The N staging system in nasopharyngeal carcinoma with radiation therapy oncology group guidelines for lymph node levels based on magnetic resonance imaging［J］.Clinical Cancer Research,2008,14(22):7497-7503.
[17]LEE N,HARRIS J,GARDEN AS,et al.Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma:Radiation therapy oncology group phase Ⅱ trial 0225［J］.Journal of Clinical Oncology,2009,27(22):3684-3690.
[18]AL-SARRAF M,LEBLANC M,GIRI PG,et al.Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer:phase Ⅲ randomized Intergroup study 0099［J］.J Clin Oncol,1998,16(4):1310-1317.
[19]SUN Y,LI WF,CHEN NY,et al.Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma:a phase 3,multicentre,randomised controlled trial［J］.Lancet Oncol,2016,17(11):1509-1520.
[20]RISCHIN D,CORRY J,SMITH J,et al.Excellent disease control and survival in patients with advanced nasopharyngeal cancer treated with chemoradiation［J］.J Clin Oncol,2002,20(7):1845-1852.
[21]HUI EP,MA BB,LEUNG SF,et al.Randomized phase Ⅱ trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma［J］.J Clin Oncol,2009,27(2):242-249.
[22]CAO S,YANG Q,GUO L,et al.Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma:A phase Ⅲ multicentre randomised controlled trial［J］.European Journal of Cancer,2017,75:14-23.
[23]TAN T,LIM WT,FONG KW,et al.Concurrent chemo-radiation with or without induction gemcitabine,Carboplatin,and Paclitaxel:a randomized,phase 2/3 trial in locally advanced nasopharyngeal carcinoma［J］.Int J Radiat Oncol Biol Phys,2015,91(5):952-960.
[24]XU T,ZHU G,HE X,et al.A phase Ⅲ randomized study comparing neoadjuvant chemotherapy with concurrent chemotherapy combined with radiotherapy for locoregionally advanced nasopharyngeal carcinoma:Updated long-term survival outcomes［J］.Oral Oncology,2014,50(2):71-76.
[25]LEE A,TUNG SY,NG WT,et al.A multicenter,phase 3,randomized trial of concurrent chemoradiotherapy plus adjuvant chemotherapy versus radiotherapy alone in patients with regionally advanced nasopharyngeal carcinoma:10-year outcomes for efficacy and toxicity［J］.Cancer,2017,123(21):4147-4157.
[26]LEE AW,TUNG SY,CHUA DT,et al.Randomized trial of radiotherapy plus concurrent-adjuvant chemotherapy vs radiotherapy alone for regionally advanced nasopharyngeal carcinoma［J］.J Natl Cancer Inst,2010,102(15):1188-1198.
[27]LI Z,LI Y,YAN S,et al.Nimotuzumab combined with concurrent chemoradiotherapy benefits patients with advanced nasopharyngeal carcinoma［J］.OncoTargets and Therapy,2017,10:5445-5458.
[28]HUANG J,ZOU Q,QIAN D,et al.Intensity-modulated radiotherapy plus nimotuzumab with or without concurrent chemotherapy for patients with locally advanced nasopharyngeal carcinoma［J］.OncoTargets and Therapy,2017,10:5835-5841.

Memo

Memo:
-
Last Update: 2022-01-27